Monday, July 25th, 2022 @ 7:37PM

Research agreements with Mayo Clinic and University of Kansas Medical Center puts industry spotlight on up-and-coming bio-tech

Stella Diagnostics, Inc. (OTC: SLDX), is focused on developing molecular diagnostic strategies for early detection of esophageal cancer. The Company, in collaboration with the Mayo Clinic, Kansas University Medical Center and mProbe, Inc., is working to improve patient management protocols for 60 million people living with sever esophageal disease.

SLDX plans to use targeted mass spectrometry proteomics to analyze biological samples. In non-medical terms, this means that with a tiny slice of an existing biopsy, Stella Diagnostics can tell if that patient will suffer from esophageal cancer 2.4 years earlier than current diagnostic protocols. 

In February, the Company announced that its STLA101 mass spec proteomic assay (BEsmart) was selected as the winner of the “Best Clinical Proteomics Solution of the Year” award for 2021 in the inaugural awards program conducted by BioTech Breakthrough.

Key Metrics @ 07/22/2022

Closing Price	$0.40
Market Cap	$19.61M
52 -Week Range	$0.15 – $1.76
Average 10-day Daily Share Volume	16,200
Average 30-day Daily Share Volume:	11,005
Shares Outstanding	98.03M
Restricted	81.49M
Unrestricted	16.51M
Shares Held at DTC	16.50M
Shares in Public Float	158,397 as of May 19, 2022
Most Recent OTC Filing: Quarterly Report	Dated 03/31/2022 – Filed:  05/19/2022
Fiscal Year-end	12/31

(Source: OTC Markets, Yahoo Finance)

Corporate News

Stella Diagnostics and Mayo Clinic to Present Data on the Utility of the STLA101 Test for Esophageal Cancer Staging at the 2022 AGA Digestive Disease Week Conference

SALT LAKE CITY, May 11, 2022 (GLOBE NEWSWIRE) — Stella Diagnostics, Inc. (OTC: SLDX), a molecular diagnostics-based organization optimizing patient management strategies for precancerous and cancerous esophageal diseases, announced today that its abstract titled “Markers in STLA101 Assay Detects Differential Expression to Distinguish Between Intramucosal and Invasive Esophageal Adenocarcinoma” has been selected for presentation during Digestive Disease Week (DDW) 2022.

 The conference will take place May 21–24, 2022 at the San Diego Convention Center in San Diego, CA. DDW 2022 is the annual meeting of The American Gastroenterological Association (AGA). Previous DDW conferences have had over 19,000 registrants.

Click on above link to read the rest of the story

Stella Diagnostics Named ‘Best Clinical Proteomics Solution’ of 2021 by Biotech Breakthrough Awards

 BioTech Breakthrough Awards recognizes the world’s best Life Sciences and Biotechnology companies, products and services

SALT LAKE CITY, (GLOBE NEWSWIRE) — Stella Diagnostics, Inc. (OTC: SLDX), a molecular diagnostics-based organization optimizing patient management strategies for precancerous and cancerous esophageal diseases, announced its STLA101 mass spec proteomic assay (BEsmart™) was selected as the winner of the “Best Clinical Proteomics Solution of the Year” award for 2021.

This is the inaugural awards program conducted by BioTech Breakthrough and attracted more than 1,200 nominations from over 12 different countries throughout the world.

Click on above link to read the rest of the story

Six reasons to consider buying SLDX now:

1. Very attractive entry point in $0.40 range – 52-week high on Feb 10 was $1.76
2. Unusually tight float – relatively little buying could run stock higher in a matter of days
3. Research agreements with the Mayo Clinic and the University of Kansas Medical Center, plus presentations at multiple industry conferences have focused a great deal of attention on the Company
4. Total Addressable Market: $3.03 Billion
5. Leadership team has extensive domain, public company and capital markets experience
6. Board of Directors is a “powerhouse” of Wall Street players including Peter Cohen, ex-CEO and Chairman of Shearson Lehman – American Express plus key principals from the Mastiff Group, Keystone Capital Partners, and Brownstone Investment Group

Bottom Line Observation

SLDX seems to be poised for a significant upward movement in the short term… with a modest amount of buying pressure.

Interested investors, especially those focused on up-and-coming bio-tech companies, definitely want to keep SLDX on their radar screens or even start building a position in the shares.

__________________________________________________________________________

Disclaimer and Disclosures: MicroCap MarketPlace (MCMP) is a financial publisher and not a FINRA broker/dealer or investment adviser. MCMP is not registered with the SEC / U.S. Securities and Exchange Commission or any state securities regulatory agency. Readers, subscribers and web site visitors are responsible for individual investment decisions. All information contained in our newsletters or on our web site and in our blogs should be independently verified with the featured companies and readers should always conduct their own research and due diligence and engage professional investment advisers as they deem appropriate before making investment decisions. Please review the Terms and Conditions of Use, including without limitation all disclaimers of warranties and limitations on liability contained therein. Your use of any information on our websites, contained herein or in our newsletters and blogs constitutes your agreement of same. MCMP did not receive any compensation for this article. However, officers, employees and affiliates may hold positions in the featured securities discussed in our newsletters or on our web site and blogs and may buy or sell said securities at any time without further notice. MCMP and/or affiliates may from time to time receive cash and/or equity compensation for corporate communications services about featured companies. In the interest of full disclosure, Mike Casson, MCMP’s Executive Editor and president of Casson Communications, LLC (CCLLC), an affiliated company, received cash compensation from OTC Stock Review for corporate communication services for the subject company. You should be aware of these potential conflicts of interest. We believe the information contained herein and, in our publications, to be reliable but cannot guarantee its accuracy; therefore, all information is provided as is without warranty of any kind. Past results are not necessarily indicative of future performance.

Research and Editorial Staff

MicroCapMarketPlace.com

© 2022 MicroCap MarketPlace, All Rights Reserved

Posted by AIA Research & Editorial Staff
Categories: Uncategorized